Emergent Stability Testing for HIV Adenoviral Vaccine Candidates
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute of Allergy and Infectious Diseases (NIAID) intends to award a sole source, firm-fixed price purchase order to Emergent Product Development Gaithersburg Inc. for Emergent Stability Testing for HIV Adenoviral Vaccine Candidates. This action is for the maintenance of critical Biologics Master Files. Responses from interested vendors are due April 23, 2026.
Purpose & Scope
NIAID, Division of AIDS (DAIDS), plans to negotiate with Emergent Product Development Gaithersburg Inc. to maintain Biologics Master File 018816 (HIV-1 Adenovirus Type 4-Vectored Vaccines) and Biologics Master File 14883 (A549 Master Cell Bank). Emergent owns these master files, which are essential for NIAID to update IND 030255. The requirement includes maintaining BB-MF 018816 through remaining 84, 96, 108, and 120-month stability timepoints, and Emergent will fund annual report submissions for BB-MF 14883 from October 2025 to October 2029.
Contract Details
- Type: Notice of Intent to Sole Source (Firm-Fixed Price Purchase Order)
- Authority: 41 U.S.C. 3304(a)(1), FAR 13.106-1(b)(2) and 13.501(a) (Only One Responsible Source)
- NAICS Code: 541714 – Research and Development in Biotechnology (Except Nanobiotechnology)
- Product Service Code: Q301 – Medical – Laboratory Testing
- Set-Aside: N/A (Emergent is a large business)
- Period of Performance:
- Base: April 27, 2026 – March 31, 2027
- Option Year 1: April 1, 2027 – March 31, 2028
- Option Year 2: April 1, 2028 – March 31, 2029 Note: A lapse in performance from October 1, 2025, to April 26, 2026, will be covered by a reinstatement included in the award pricing.
Response Information
- Response Due: April 23, 2026, 12:00 PM EST
- Published Date: April 21, 2026
- Contact: Linda Smith, Contracting Officer, Linda.Smith2@nih.gov
- Action: This is not a request for competitive quotations. However, firms believing they can meet the requirement may submit a capabilities statement, including past performance, in writing to the identified point of contact within 10 days after publication of this notice. This documentation will be evaluated to determine if a competitive procurement is feasible.